Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
May 1956

A Rational Therapy of Systemic Lupus Erythematosus

Author Affiliations

Long Beach, Calif.

From the Department of Medicine, University of California Medical Center, Los Angeles, and the Veterans Administration Hospital, Long Beach.

AMA Arch Intern Med. 1956;97(5):562-575. doi:10.1001/archinte.1956.00250230056006

Our limited knowledge of systemic lupus erythematosus has restricted therapy to empirical and symptomatic approaches. Only corticotropin (ACTH) and the adrenal steroids have been generally accepted as valuable,1 and it is doubtful that these influence the underlying disease.2 Their benefit is probably due to their anti-inflammatory effect. It is the purpose of this paper to report a therapeutic regimen based upon observations 3 on the L. E.-cell phenomenon.4

Klemperer and co-workers 5 have reported that both the L. E.-cell bodies and the hematoxylin bodies found in tissues of patients with lupus contain depolymerized deoxyribonucleic acid (DNA). DNA occurs only in the chromosomes of cell nuclei and is thought to be the principal constituent of the gene, the carrier of hereditary characters. The breakdown of this molecule is probably not compatible with cell survival.

The L. E. cell, thus, represents a nucleolytic phenomenon. The depolymerized nuclear material may

First Page Preview View Large
First page PDF preview
First page PDF preview